KEVIN TABB SAYS ‘THANK YOU’
Through your remarkable generosity, BIDMC once again set the bar for fundraising totals in FY’14. Kevin Tabb, M.D., BIDMC President and CEO, is truly proud of the support and dedication to the Medical Center shown by friends and partners.
ADVANCING NEPHROLOGY EDUCATION AND TRAINING
Cathy Bernstein, Geoffrey Bernstein, and Michael Bernstein made a generous gift of $500,000 in memory of their husband and father, Stanley J. Bernstein, to support the work of Robert Cohen, M.D., in the field of nephrology.
With a focus on eliminating preventable harm and boosting patient safety, the Gordon and Betty Moore Foundation made a $5.4 million pledge in 2013 to the intensive care unit (ICU) at Beth Israel Deaconess Medical Center.
UTILIZING THE POWER OF RNA
The Bernstein family exhibited its dedication to Dr. Cohen, Senior Nephrologist and the Director of Education with the Nephrology Division at Beth Israel Deaconess Medical Center, by making this incredible gift. Their commitment will support Dr. Cohen’s development of the National Communication Skills Curriculum Development in Nephrology, which will greatly enhance complex patient-doctor communications for generations to come. Funds will also go to the Annual Bernstein-Harvard Nephrology Fellows' Communication Skills-Building Workshop and Stanley J. Bernstein Lecture on Peritoneal Dialysis/Chronic Kidney Disease as part of an endowment to honor Stan’s legacy. The Bernsteins’ visionary support toward building innovative educational programming will advance BIDMC and other institutions at the local and national level to vastly improve the clinical experience for patients with advanced kidney disease.
The Gordon and Betty Moore Foundation demonstrated its commitment to improving the experience and outcomes of patient care by generously supporting a unique initiative to address a variety of potential risks in the ICU at BIDMC. The project will use information technology and systems science to increase family involvement in decision-making while promoting patient dignity and respect. Kenneth Sands, M.D., M.P.H., Chief Quality Officer at BIDMC, and Daniel Talmor, M.D., acting chair of the Department of Anesthesia, Critical Care and Pain Medicine at BIDMC, are spearheading the program. The foundation’s impressive commitment will allow Drs. Sands and Talmor continue to innovate and improve clinician, patient, and family engagement while finding new ways to identify and manage risks.
Along with graciously hosting dinner in honor of BIDMC Cancer Center Director Pier Paolo Pandolfi, M.D., Ph.D., in May 2014, the Micozzis showed their dedication to the iRM by making this significant pledge in 2013. Dr. Pandolfi, a distinguished cancer geneticist, and molecular biologist John Rinn, Ph.D., co-founded the iRM. MicroRNA expert Frank Slack, Ph.D., joined Drs. Pandolfi and Rinn in July 2014 to serve as iRM Director and help set BIDMC apart in cancer research and bring non-coding RNA laboratory discoveries into the clinical setting. This commitment from these important members of the BIDMC family will help the iRM continue to have a variety of resources to tap into for research, including the Cancer Center’s “Mouse Hospital.” These mouse models allow physicians to move from research to clinical trials to analyze the effectiveness of new treatment options that could eventually be used for humans.
BIDMC is fortunate to have the remarkable support of the Trust Family Foundation, which helped create the Martin and Diane Trust Career Development Chair in Surgery. The chair will provide two to five years of salary and research support for early- or mid-career faculty of great promise, which will be crucial to fulfilling their potential. Peter Chang, M.D., M.P.H., is Director of the multidisciplinary BIDMC Prostate Cancer Care Center and currently serves as the initial incumbent of the new Career Development Chair. This generosity will allow Dr. Chang, who also completed a two-year fellowship at BIDMC in minimally invasive urologic oncology, to continue to provide exceptional care for patients with bladder cancer and other urologic conditions.
A HEARTFELT THANK YOU
It is an honor to recognize and thank our outstanding supporters and partners for the remarkable successes of Beth Israel Deaconess Medical Center’s last fiscal year. With an impressive fundraising total of nearly $54 million, the most raised in a single year in the history of BIDMC, we continued our efforts to fund groundbreaking research and drive our commitment to academic excellence.
Your generosity enables our institution to provide the highest level of care to our patients and their families. It provides critical funding for leading-edge research, and allows us to train the next generation of leaders in health care. On behalf of the BIDMC community and the patients who will benefit from this important work, thank you for your support.
- Kevin Tabb, M.D., President and CEO of Beth Israel Deaconess Medical Center